About Our Project
Antimicrobial Resistance (AMR) is a growing concern, resulting in an estimated 10 million deaths worldwide by 2050 – more than cancer and diabetes combined.
Every use of an antibiotic comes with a risk that resistance might develop. However, between 20-50% of antibiotics prescribed are unnecessary or inappropriate and this has a clear impact on the health outcomes and costs in care for both the individual and society.
The correct choice of antibiotic gives a triple benefit: better treatment for the patient, less money spent on consuming the wrong antibiotics, and ultimately the reduction of AMR by selecting the right drug for the right bug.
Abtrace uses artificial intelligence techniques to better understand clinical decisions and provide the clinician with the information that will aid a better choice, instantly, for every patient and every prescription.
You can find out more on our website.
Meet the Team
Each of us had seen the effects of antimicrobial resistance in our professional or personal lives.
Our personalities and skills complement each other, with a good mix of idealistic vs pragmatic, scientific vs clinical and academic vs commercial approaches. It has been a challenging journey at times, but we loved working together and successfully managed to overcome every obstacle so far with a strong team spirit.
Umar Naeem Ahmad
Umar Naeem Ahmad is a clinician with experience in Infectious Disease, Intensive Care and Emergency Medicine, based in the UK. He has worked on projects in 9 countries, ranging from the WHO in Switzerland to the Ebola response in Sierra Leone. He has been managing healthcare workers and transforming clinical pathways to improve quality of care through digital solutions.
Cristina Correia brings strong experience in medical device product development, business development and regulatory affairs, having managed R&D teams and funds towards consistent generation of scientific publications and intellectual property. She is a graduate of Biomedical Engineering and is based in Portugal.
Helder Soares is trained in Medicinal Chemistry, also based in Portugal. Helder is skilled in effectively leading research teams both in academia and in the pharmaceutical industry holding intellectual property on novel solutions for antimicrobial resistance.
Abtrace and EIT Health
During the Wild Card CRAASH business model validation programme, our project was received with great enthusiasm and interest from key players both in Portugal and the UK, ranging from physicians in primary and secondary care, clinical record providers and policy makers.
They recognised the need for this solution, shared our vision and wanted to help.
As a result, we will be based in the Instituto Pedro Nunes, in Coimbra, but have been collaborating with partners across Europe. EIT Health has been of great value in providing the technical mentoring, business expertise, legal consultancy as well as access to their extensive network of brilliant people and key organisations.
Our Wild Card Experience
Wild Card has been a rollercoaster of challenges and emotions, and a unique learning experience. EIT Health set up this programme designed to support game changing ideas in the healthcare field and in the next few months we hope to be walking that path towards revolutionising the way antibiotics are prescribed.
The Abtrace approach can and is urgently needed to fight back against the rising threat of AMR.